---
title: "RTW 生物科技對諾華製藥收購其投資公司 Avidity Biosciences 表示讚賞"
description: "RTW 生物科技機會有限公司注意到諾華製藥與 Avidity Biosciences 達成協議，以每股 72 美元收購該公司，較 Avidity 最近的收盤價溢價 46%，這使得該公司的估值約為 120 億美元。RTW 持有 Avidity 淨資產價值的 7%，預計 Avidity 的子公司 SpinCo 將在收購後開始交易。這標誌着 RTW 自 6 月 30 日以來的第五次投資組合退出，突顯了 "
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/262887935.md"
published_at: "2025-10-27T11:45:31.000Z"
---

# RTW 生物科技對諾華製藥收購其投資公司 Avidity Biosciences 表示讚賞

> RTW 生物科技機會有限公司注意到諾華製藥與 Avidity Biosciences 達成協議，以每股 72 美元收購該公司，較 Avidity 最近的收盤價溢價 46%，這使得該公司的估值約為 120 億美元。RTW 持有 Avidity 淨資產價值的 7%，預計 Avidity 的子公司 SpinCo 將在收購後開始交易。這標誌着 RTW 自 6 月 30 日以來的第五次投資組合退出，突顯了 RNA 治療在製藥行業中的戰略重要性

(Alliance News) - RTW Biotech Opportunities Ltd on Monday noted that Swiss pharmaceutical major Novartis AG has definitively agreed to buy portfolio company Avidity Biosciences Inc.

RTW, a Guernsey-based investor in the life sciences sector, said Avidity stockholders will receive USD72 per share in cash upon the deal's closing. This represents an approximate 46% premium to Avidity's USD49.15 per share closing price on Friday, and values the California-based clinical-stage biotechnology firm at around USD12 billion.

Shares in RTW were 3.3% higher at USD1.76 each on Monday morning in London.

RTW said Avidity, which is developing RNA therapeutics for rare muscle diseases, represents 7.0% of its net asset value and is RTW's third-biggest holding. It expects Avidity's subsidiary SpinCo to begin trading as a new public company, following its spin-off as part of the deal.

Basel, Switzerland-based pharmaceutical company Novartis announced on Sunday that it had agreed to purchase Avidity.

"Avidity was the first to achieve targeted RNA delivery into muscle tissue and is expanding its pipeline into cardiology and immunology," RTW noted.

It explained that before the acquisition closes, Avidity will transfer to SpinCo, with Avidity shareholders receiving one SpinCo share per ten Avidity shares, and/or cash from Avidity's proceeds "if certain SpinCo assets are, or SpinCo itself is, sold to a third party".

"Avidity's acquisition by Novartis represents a successful conclusion to a relationship begun when RTW led Avidity's crossover financing round in 2019, ahead of its 2020 \[initial public offering\]," commented RTW's Chief Investment Officer Rod Wong. "This transaction marks the fifth take-out from RTW Bio's portfolio announced since 30 June, following deals for Verona, Alcyone, Merus, and Akero. Each acquisition reflects strong conviction in differentiated science and late-stage clinical potential.

"Novartis's acquisition of Avidity underscores the strategic value of RNA therapeutics in neuromuscular disease and the urgency among large pharma to secure assets that can drive growth beyond upcoming patent expiries."

By Emma Curzon, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2025 Alliance News Ltd. All Rights Reserved.

### Related Stocks

- [NVS.US - 諾華制藥](https://longbridge.com/zh-HK/quote/NVS.US.md)
- [RNA.US - Avidity Biosciences](https://longbridge.com/zh-HK/quote/RNA.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 美股夜盘异动：诺华 23 亿投资计划提振市场信心，夜盘股价上涨 3.74% | 诺华制药夜盘涨 3.74%；诺和诺德公司夜盘涨 0.83%，成交额达到 3.54 百万美元；礼来夜盘涨 0.59%，成交额达到 2.52 百万美元；脑再生科技夜盘涨 16.34%，成交额达到 70.11 万美元。 | [Link](https://longbridge.com/zh-HK/news/272208978.md) |
| 诺华制药 Vanrafia(R) 的三期临床数据支持其在减缓 IgA 肾病患者肾功能下降方面的效果 | （更多内容即将发布）道琼斯新闻社 2026 年 2 月 13 日 01:15 ET（06:15 GMT） | [Link](https://longbridge.com/zh-HK/news/275856996.md) |
| 奥本海默资产管理公司增持了诺华制药的股份 $NVS | Oppenheimer Asset Management Inc. 在第三季度将其在诺华制药的持股增加了 6.4%，目前持有 222,892 股，价值 2858 万美元。其他机构投资者也调整了他们的持仓，其中 Cardinal Point  | [Link](https://longbridge.com/zh-HK/news/275286511.md) |
| Erste Group 维持对诺华制药（NOVN）的买入评级 | Erste Group 于 1 月 23 日对诺华制药 (NOVN) 维持了买入评级，收盘价为 CHF115.64。分析师 Stephan Lingnau 是一位 3 星分析师，平均回报率为 9.7%，表示该股票的共识评级为适度买入，平均目 | [Link](https://longbridge.com/zh-HK/news/273732689.md) |
| SciNeuro 授予诺华制药阿尔茨海默病药物的开发权 | SciNeuro 授予诺华制药阿尔茨海默病药物的权利 | [Link](https://longbridge.com/zh-HK/news/272511348.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。